Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Autoimmune hepatitis: current challenges and future prospects.

Aizawa Y, Hokari A.

Clin Exp Gastroenterol. 2017 Jan 19;10:9-18. doi: 10.2147/CEG.S101440. Review.

2.

Association of GSTO2 (N142D) Genetic Polymorphism and Acute Rejection of Liver.

Khosravi M, Saadat I, Karimi MH, Malek Hosseini SA.

Int J Organ Transplant Med. 2016;7(3):183-187.

3.

Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells.

Arterbery AS, Osafo-Addo A, Avitzur Y, Ciarleglio M, Deng Y, Lobritto SJ, Martinez M, Hafler DA, Kleinewietfeld M, Ekong UD.

J Immunol. 2016 May 15;196(10):4040-51. doi: 10.4049/jimmunol.1502276.

PMID:
27183637
4.

De novo autoimmune hepatitis in liver transplant: State-of-the-art review.

Vukotic R, Vitale G, D'Errico-Grigioni A, Muratori L, Andreone P.

World J Gastroenterol. 2016 Mar 14;22(10):2906-14. doi: 10.3748/wjg.v22.i10.2906. Review.

5.

Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis.

Amarapurkar D, Amarapurkar A.

J Clin Exp Hepatol. 2015 Dec;5(4):314-9. doi: 10.1016/j.jceh.2015.08.005.

6.

Recurrence of autoimmune liver diseases after liver transplantation.

Faisal N, Renner EL.

World J Hepatol. 2015 Dec 18;7(29):2896-905. doi: 10.4254/wjh.v7.i29.2896. Review.

7.

Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.

Edmunds C, Ekong UD.

Transplantation. 2016 Mar;100(3):515-24. doi: 10.1097/TP.0000000000000922. Review.

8.

De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis: an unusual cause of late grafts dysfunction.

Ennaifer R, Ayadi H, Romdhane H, Cheikh M, Mestiri H, Khalfallah T, Hadj NB.

Pan Afr Med J. 2015 May 4;21:2. doi: 10.11604/pamj.2015.21.2.6789.

9.

Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.

Masola V, Carraro A, Zaza G, Bellin G, Montin U, Violi P, Lupo A, Tedeschi U.

BMC Gastroenterol. 2015 Sep 14;15:118. doi: 10.1186/s12876-015-0347-6.

10.

Biliary complications after pediatric liver transplantation: Risk factors, diagnosis and management.

Feier FH, da Fonseca EA, Seda-Neto J, Chapchap P.

World J Hepatol. 2015 Aug 28;7(18):2162-70. doi: 10.4254/wjh.v7.i18.2162. Review.

11.

ABO-compatible liver allograft antibody-mediated rejection: an update.

Demetris AJ, Zeevi A, O'Leary JG.

Curr Opin Organ Transplant. 2015 Jun;20(3):314-24. doi: 10.1097/MOT.0000000000000194. Review.

12.

Liver transplantation and autoimmune hepatitis.

Tanaka T, Sugawara Y, Kokudo N.

Intractable Rare Dis Res. 2015 Feb;4(1):33-8. doi: 10.5582/irdr.2014.01034. Review.

13.

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.

Kim H, Yi NJ, Lee J, Kim J, Moon MR, Jeong J, Lee JM, You TS, Suh SW, Park MS, Choi Y, Hong G, Lee HW, Lee KW, Suh KS.

Clin Mol Hepatol. 2014 Sep;20(3):291-9. doi: 10.3350/cmh.2014.20.3.291.

14.

Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M.

World J Transplant. 2014 Jun 24;4(2):133-40. doi: 10.5500/wjt.v4.i2.133.

15.

Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation.

Sanada Y, Matsumoto K, Urahashi T, Ihara Y, Wakiya T, Okada N, Yamada N, Hirata Y, Mizuta K.

World J Gastroenterol. 2014 Jun 7;20(21):6638-50. doi: 10.3748/wjg.v20.i21.6638.

16.

Q-FISH measurement of hepatocyte telomere lengths in donor liver and graft after pediatric living-donor liver transplantation: donor age affects telomere length sustainability.

Kawano Y, Ishikawa N, Aida J, Sanada Y, Izumiyama-Shimomura N, Nakamura K, Poon SS, Matsumoto K, Mizuta K, Uchida E, Tajiri T, Kawarasaki H, Takubo K.

PLoS One. 2014 Apr 11;9(4):e93749. doi: 10.1371/journal.pone.0093749.

17.

Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Liu B, Li J, Yan LN.

Clin Dev Immunol. 2013;2013:325318. doi: 10.1155/2013/325318. Review.

18.

Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.

Locke JE, Singer AL.

Hepat Med. 2011 May 13;3:53-62. doi: 10.2147/HMER.S13682. Review.

19.

Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers.

Wei L, Gong X, Martinez OM, Krams SM.

Transpl Immunol. 2013 Dec;29(1-4):123-9. doi: 10.1016/j.trim.2013.08.005. Review.

20.

Significance of semiquantitative assessment of preformed donor-specific antibody using luminex single bead assay in living related liver transplantation.

Yoshizawa A, Egawa H, Yurugi K, Hishida R, Tsuji H, Ashihara E, Miyagawa-Hayashino A, Teramukai S, Maekawa T, Haga H, Uemoto S.

Clin Dev Immunol. 2013;2013:972705. doi: 10.1155/2013/972705.

Supplemental Content

Support Center